Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in ...

Novo Nordisk said the mainly debt-financed acquisition is expected to have a mid-single-digit negative impact on 2025 operating profit growth and the company isn’t expecting to start a share ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Novo Nordisk to invest $1.2 billion in Denmark for a new production site ... impacting Novo Nordisk’s 2024 profit and 2025 share buyback plans. On Monday, Danish pharmaceutical firm Novo ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and ...

The 40,000-square-metre (430,000-square-feet) production facility and warehouse in Odense "marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new ...

Novo Nordisk plans to invest $1.2 billion in a new production site for rare-disease medicines in Denmark. The Danish ... negative impact on 2025 operating profit growth and the company isn't ...

The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing ... A slight negative effect on operating profit growth and a reduction in free ...